to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
Engineering opportunities in cancer immunotherapy.
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.
Immunomodulatory roles of lymphatic vessels in cancer progression.
6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
Engineering approaches to immunotherapy.
Trojan horses for immunotherapy.
Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers.
Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy.
Overcoming transport barriers to immunotherapy.
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker.
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01
Membrane-localized neoantigens predict the efficacy of cancer immunotherapy.
Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity.
Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy.